Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: Misuse, cognitive impact, and adverse effects

Brain and Behavior

Volumn 2, Issue 5, 2012, Pages 661-677

  Lakhan, Shaheen E ^a   Kirchgessner, Annette ^a  

^a Global Neuroscience Initiative Foundation   (United States)

Author keywords

Amphetamine; Athletes; Attention deficit hyperactivity disorder; Cognition; Methylphenidate; Misuse; Performance; Students

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; PERFORMANCE ENHANCING SUBSTANCE; PSYCHOSTIMULANT AGENT;

ANOREXIA; ARTICLE; ATHLETE; ATTENTION DEFICIT DISORDER; BLUNTED AFFECT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COGNITION; COLLEGE STUDENT; DELUSION; DRUG MISUSE; DRUG OVERDOSE; HEART ARRHYTHMIA; HEART INFARCTION; HIGH SCHOOL STUDENT; HUMAN; HYPERTENSION; INSOMNIA; LIVER TOXICITY; LONG TERM CARE; MENTAL DISEASE; NECROTIZING ARTERITIS; PERFORMANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SPORT; SUDDEN DEATH; SUICIDAL IDEATION; TACHYCARDIA; VISUAL HALLUCINATION;

EID: 84882808169     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.78     Document Type: Article

References (139)

1. Advokat, C. 2010. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci. Biobehav. Rev. 34:1256-1266.
2. Advokat, C. D., M. S. Guidry, and B. A. Martino 2008. Licit and illicit use of medications for attention deficit hyperactivity disorder in undergraduate college students. J. Am. Coll. Health 56:601-607.
3. Alsidawi, S., J. Muth, and J. Wilkin 2011. Adderall induced inverted-Takotsubo cardiomyopathy. Catheter. Cardiovasc. Interv. 78:910-913.
4. Amariles, P. 2011. A comprehensive literature search: drugs as possible triggers of Takotsubo cardiomyopathy. Curr. Clin. Pharmacol. 6:1-11.
5. American Psychiatric Association. 2000. DSM-IV-TR. American Psychiatric Association, Washington, DC.
6. Associated Press. 2009.ADHD exemptions on rise in MLB. ESPN, New York, NY.
7. Barch, D. M., and C. S. Carter 2005. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Res. 77:43-58.
8. Barkley, R. A., and C. E. Cunningham 1978. Do stimulant drugs improve the academic performance of hyperkinetic children? A review of outcome studies. Clin. Pediatr. (Phila.) 17:85-92.
9. Barrett, S. P., C. Darredeau, L. K. Brody, and R. O. Pihl 2005. Characteristics of methylphenidate misuse in a university student sample. Can. J. Psychiatry 50:457-461.
10. Biederman, J., M. C. Monuteaux, E. Mick, T. Spencer, T. E. Wilens, J. M. Silva, et al. 2006. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10 year prospective follow-up study. Psychol. Med. 36:167-179.
11. Biederman, J., C. R. Petty, R. Fried, R. Kaiser, C. R. Dolan, S. Schoenfeld, et al. 2008a. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J. Clin. Psychiatry 69:1217-1222.
12. Biederman, J., L. J. Seidman, C. R. Petty, R. Fried, A. E. Doyle, D. R. Cohen, et al. 2008b. Effects of stimulant medication on neuropsychological functioning in young adults with attention deficit/hyperactivity disorder. J. Clin. Psychiatry 69:1150-1156.
13. Biederman, J., R. Fried, C. R. Petty, A. Henin, J. Wozniak, L. Corkum, et al. 2012. Examining the association between stimulant treatment and cognitive outcomes across the life cycle of adults with attention-deficit/hyperactivity disorder: a controlled cross-sectional study. J. Nerv. Ment. Dis. 200:69-75.
14. Bloom, B., and R. A. Cohen 2007. Summary health statistics for U.S. children: National Health Interview Survey, 2006. Statistics VH 234:1-79.
15. Bogle, K. E., and B. H. Smith 2009. Illcit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr. Drug Abuse Rev. 2:157-176.
16. Bray, C. L., K. S. Cahill, J. T. Oshier, C. S. Peden, D. W. Theriaque, T. R. Flotte, et al. 2004. Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults. J. Invest. Med. 52:192-201.
17. Breitenstein, C., S. Wailke, S. Bushuven, S. Kamping, P. Zwitserlood, E. B. Ringelstein, et al. 2004. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology 29:1704-1714.
18. Breitenstein, C., A. Floel, C. Korsukewitz, S. Waike, S. Bushuven, and S. Knecht 2006. A shift paradigm: from noradrenergic to dopaminergic modulation of learning? J. Neurol. Sci. 248:42-47.
19. Brignell, C. M., J. Rosenthal, and H. V. Curran 2007. Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. J. Psychopharmacol. 21:673-683.
20. Brown, R. T., R. W. Amler, W. S. Freeman, J. M. Perrin, M. T. Stein, H. M. Feldman, et al. 2005. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 115:e749-e757.
21. Brumaghim, J. T., and R. Klormart 1998. Methylphenidate's effects on paired-association learning and event-related potentials of young adults. Psychophysiology 35:73-85.
22. Burns, J. T., R. F. House, F. C. Fensch, and J. G. Miller 1967. Effects of magnesium pemoline and dextroamphetamine on human learning. Science 155:849-851.
23. Callaway, E. 1983. Presidential address. 1982: the pharmacology of human information processing. Psychophysiology 20:359-370.
24. Camp-Bruno, J. A., and R. L. Herting 1994. Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology 115:46-52.
25. Center for Disease Control and Prevention. 2005a. Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003. MMWR Morb. Mortal. Wkly. Rep. 54:842-847.
26. Center for Disease Control and Prevention. 2005b. Prevalence of diagnosis and medication treatment for attention deficit/hyperactivity disorder - United States, 2003. MMWR Morbid. Mortal. Wkly. Rep. 54:842-847.
27. Centers for Disease Control and Prevention. 2010. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children - United States, 2003 and 2007. MMWR Morb. Mortal. Wkly. Rep. 59:1439-1443.
28. Chen, J. P. 2007. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J. Invasive Cardiol. 19:E89-E92.
29. Clatworthy, P. L., S. J. Lewis, L. Brichard, Y. T. Hong, D. Izquierdo, L. Clark, et al. 2009. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J. Neurosci. 29:4690-4696.
30. Cooper, N. J., H. Keage, D. Hermens, L. M. Williams, D. Debrota, and C. R. Clark 2005. The dose-dependent effect of methylphenidate on performance, cognition, and psychophysiology. J. Integrative Neurosci. 4:123-144.
31. Cooper, W. O., L. A. Habel, C. M. Sox, K. A. Chan, P. G. Arbogast, T. C. Cheetham, et al. 2011. ADHD drugs and serious cardiovascular events in children and young adults. N. Engl. J. Med. 365:1896-1904.
32. Department of Justice: Drug Enforcement Administration. 2008. ARCOS2-report 7, United States summary for retail drug purchases by grams weight.
33. Dodds, C. M., U. Muller, L. Clark, A. van Loon, R. Cools, and T. W. Robbins 2008. Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J. Neurosci. 28:5976-5982.
34. Dopheide, J. A., and S. R. Pliszka 2009. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29:656-679.
35. Elia, J., P. J. Ambrosini, and J. L. Rapoport 1999. Treatment of attention-deficit-hyperactivity disorder. N. Engl. J. Med. 340:780-788.
36. Elliott, R., B. J. Sahakian, K. Matthews, A. Bannerjea, J. Rimmer, and T. W. Robbins 1997. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131:196-206.
37. European Medicines Agency. 2007. Meeting highlights from the committee for medicinal products for human use, 16-19 July 2007, European Medicines Agency, London.
38. Farah, M. J., C. Halmm, G. Sankoorikal, M. E. Smith, and A. Chatterjee 2009. When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary study Psychopharmacology 202:541-547.
39. Faraone, S. V., and S. J. Glatt 2010. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry 71:754-763.
40. Faraone, S. V., J. Biederman, J. G. Jetton, and M. T. Tsuang 1997. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol. Med. 27:291-300.
41. Faraone, S. V., J. Sergeant, C. Gillberg, and J. Biederman 2007. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104-113.
42. Fillmore, M. T., T. H. Kelly, and C. A. Martin 2005. Effects of d-amphetamine in human models of information processing and inhibitory control. Drug Alcohol Dep. 77:151-159.
43. Fitzpatrick, P., R. Klorman, J. T. Brumaghim, and R. W. Keefover 1988. Effects of methylphenidate on stimulus evaluation and response processes: evidence from performance and event-related potentials. Psychophysiology 25:292-304.
44. Fleming, K., L. B. Bigelow, D. R. Weinberger, and T. E. Goldberg 1995. Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol. Bull. 31:357-362.
45. Gandhi, P. J., G. U. Ezeala, T. T. Luyen, T. C. Tu, and M. T. Tran 2005. Myocardial infarction in an adolescent taking Adderall. Am. J. Health Syst. Pharm. 62:1494-1497.
46. Greydanus, D. E., and V. C. Strasburger 2006. Adolescent medicine. Prim. Care 33:xiii-xviii.
47. Gualtieri, C. T., and L. G. Johnson 2008. Medications do not necessarily normalize cognition in ADHD patients. J. Atten. Disord. 11:459-469.
48. Habel, L. A., W. O. Cooper, C. M. Sox, K. A. Chan, B. H. Fireman, P. G. Arbogast, et al. 2011. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306:2673-2683.
49. Harris, S.. 2009. "I don't see it as a problem": more medical students taking prescription stimulants, few see cause for concern.
50. Herman, L., O. Shtayermman, B. Aksnes, M. Anzalone, A. Cormerals, and C. Liodice 2011. The use of prescription stimulants to enhance academic performance among college students in health care programs. J. Physician Assist. Educ. 22:15-22.
51. Hester, R., L. S. Nandam, R. G. O'Connell, J. Wagner, M. Strudwick, P. J. Nathan, et al. 2012. Neurochemical enhancement of conscious error awareness. J. Neurosci. 32:2619-2627.
52. Horrigan, J. P. 2001. Present and future pharacotherapeutic options for adult attention deficit/hyperactivity disorder. Exp. Opin. Psychopharmacol. 2:573-586.
53. Hurst, P. M., R. Radlow, N. C. Chubb, and S. K. Bagley 1969. Effects of D-amphetamine on acquisition, persistence, and recall. Am. J. Psychol. 82:307-319.
54. Jacobs, A. 2005. The Adderall advantage. The New York Times. Available at: http://www.nytimes.com/2005/07/31/education/edlife/jacobs31.html.
55. Jensen, P. S., L. E. Arnold, J. M. Swanson, B. Vitiello, H. B. Abikoff, L. L. Greenhill, et al. 2007. 3-year follow-up of the NIMH MTA study. J. Am. Acad. Child Adolesc. Psychiatry 46:989-1002.
56. Jiao, X., S. Velez, J. Ringstad, V. Eyma, D. Miller, and M. Bleiberg 2009. Myocardial infarction associated with Adderall XR and alcohol use in a young man. J. Am. Board Fam. Med. 22:197-201.
57. Johnston, L. D., P. M. O'Malley, J. G. Bachman, and J. E. Schulenberg 2004. Monitoring the future: national survey results on drug use, 1975-2003. Pp. 10-12 in NIoD, ed. Abuse. National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.
58. Kadison, R. 2005. Getting an edge - use of stimulants and antidepressants in college. N. Engl. J. Med. 353:1089-1091.
59. Kennedy, R. S., R. C. Odenheimer, D. R. Baltzley, W. P. Dunlap, and C. D. Wood 1990. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Aviat. Space Environ. Med. 61:615-621.
60. Kessler, R. C., L. Adler, R. Barkley, J. Biederman, C. K. Conners, O. Demler, et al. 2006. The prevalence and correlates of adult ADHD in the United Stated: results from the national comorbidity survey replication. Am. J. Psychiatry 163:716-723.
61. Klorman, R., L. O. Bauer, H. W. Coons, J. L. Lewis, J. Peloquin, R. A. Perlmutter, et al. 1984. Enhancing effects of methylphenidate on normal young adults' cognitive processes. Psychopharmacol. Bull. 20:3-9.
62. Koelega, H. S. 1993. Stimulant drugs and vigilance performance: a review. Psychopharmacology 111:1-16.
63. Kollins, S. H. 2003. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J. Clin. Psychol. 64:14-18.
64. Kollins, S. H. 2008. ADHD, substance use disorder, and psychostimulant treatment current literature and treatment guidelines. J. Atten. Disord. 12:115-125.
65. Kollins, S. H., F. J. McClernon, and B. F. Fuemmeler 2005. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of children aged 9 through 16 years. J. Am. Acad. Child Adolesc. Psychiatry 62:1142-1431.
66. Kuczenski, R., and D. S. Segal 1997. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68:2032-2037.
67. Kumari, V., P. J. Corr, O. F. Mulligan, P. A. Cotter, S. A. Checkley, and I. A. Gray 1997. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man: a preliminary study. Psychopharmacology 129:271-276.
68. Kutcher, J. S. 2011. Treatment of attention-deficit hyperactivity disorder in athletes. Curr. Sports Med. Rep. 10:32-36.
69. Looby, A., and M. Earleywine 2011. Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance. Exp. Clin. Psychopharmacol. 19:433-444.
70. Lord, S., G. Downs, P. Furlaw, A. Chaudhurl, A. Silverstein, A. Gammaitoni, et al. 2003. Nonmedical use of prescription opiods and stimulants among student pharmacists. J. Am. Pharm. Assoc. 49:519-528.
71. Low, K. G., and A. E. Gendaszek 2002. Illicit use of psychostimulants among college students: a preliminary study. Psychol. Health Med. 7:283-287.
72. Makris, A. P., C. R. Rush, R. C. Frederich, A. C. Taylor, and T. H. Kelly 2007. Behavioral and subjective effects of d-ampetamine and modafinil in healthy adults. Exp. Clin. Psychopharmacol. 15:123-133.
73. Masand, P., P. Pickett, and G. B. Murray 1991. Psychostimulants for secondary depression in medical illness. Psychosomatics 32:203-208.
74. Mattay, V. S., K. F. Berman, J. L. Ostrem, G. Esposito, J. D. Van Horn, and L. B. Bigelow 1996. Dextroamphetamine enhances "neural network-specific" physiological signals: a positron emission tomography rCBF study. J. Neurosci. 16:4816-4822.
75. Mattay, V. S., J. H. Callicott, A. Bertolino, I. Heaton, J. A. Frank, R. Coppola, et al. 2000. Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage 12:268-275.
76. Mattay, V. S., T. E. Goldberg, F. Fera, A. R. Hariri, A. Tessitore, M. F. Egan, et al. 2003. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Am. Sci. USA 100:6186-6191.
77. McCabe, S. E., and C. J. Boyd 2005. Sources of prescription drugs for illicit use. Addict. Behav. 30:1342-1350.
78. McCabe, S. E., C. J. Teter, and C. J. Boyd 2004. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst. Use Misuse 39:1095-1116.
79. McCabe, S. E., J. R. Knight, C. J. Teter, and H. Wechsler 2005. Nonmedical use of prescription stimulants among US college students: prevalence and correlates from a nationwide survey. Addiction 100:96-106.
80. McLaughlin, L. 2011. Adderall: the whole story. Available at: http://reesenews.org/2011/10/26/adderall-the-whole-story/19843/
81. McNiel, A. D., K. B. Muzzin, J. P. DeWald, A. L. McCann, E. D. Schneiderman, J. Scofield, et al. 2011. The nonmedical use of prescription stimulants among dental and dental hygiene students. J. Dental Edu. 75:365-376.
82. Mehta, M. A., A. M. Owen, B. J. Sahakian, N. Mavaddat, J. D. Pickard, and T. W. Robbins 2000. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 20:RC65.
83. Mintzer, M. Z., and R. R. Griffiths 2007. A triazolam/amphetamine dose-effect interaction study: dissociation of effects on memory versus arousal. Psychopharmacology 192:425-440.
84. Misener, V. L., P. Luca, O. Azeke, J. Crosbie, I. Waldman, R. Tannock, et al. 2004. Linkage of the dopamine receptor D1 gene to attention-deficit/hyperactivity disorder. Mol. Psychiatry 9:500-509.
85. Mitchell, H.. 2012. Faking ADHD Gets you into Harvard. The Daily Beast. Available at: http://www.thedailybeast.com/articles/2012/01/25/faking-adhd-gets-you-into-harvard.html
86. Molina, B. S. G., S. P. Hinshaw, J. M. Swanson, L. E. Arnold, B. Vitiello, P. S. Jensen, et al. 2009. The MTA at 8 years: prospective follow-up of children treated for combined type ADHD in the multisite study. J. Am. Acad. Child Adolesc. Psychiatry. 48:484-500.
87. Murray, J. B. 1998. Psychophysiological aspects of amphetamine-methamphetamine abuse. J. Psychol. 132:227-237.
88. Musser, C. J., P. A. Ahmann, F. W. Theye, P. Mundt, S. K. Broste, and N. Mueller-Rizner 1998. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J. Dev. Behav. Pediatr. 19:187-192.
89. Oken, B. S., S. S. Kishiyama, and M. C. Salinsky 1995. Pharmacologically induced changes in arousal: effects on behavioral and electrophysiologic measures of alertness and attention. Electroenceph Clin. Neurophysiol. 95:359-371.
90. Partridge, B. J., S. K. Bell, J. C. Lucke, S. Yeates, and W. D. Hall 2011. Smart drugs "as common as coffee": media hype about neuroenhancement. PLoS One 6:e28416.
91. Pelham W. E., Jr, K. McBurnett, G. W. Harper, R. Milich, D. A. Murphy, J. Clinton, et al. 1990. Methylphenidate and baseball playing in ADHD children: who's on first? J. Consult. Clin. Psychol. 58:130-133.
92. Piper, B. J., J. B. Fraiman, and J. S. Meyer 2005. Repeated MDMA ("Ecstasy") exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. Dev. Psychobiol. 47:145-157.
93. Polanczyk, G., M. S. de Lima, B. L. Horta, J. Biederman, and L. A. Rohde 2007. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 164:942-948.
94. Polchert, S. E., and R. M. Morse 1985. Pemoline abuse. JAMA 254:946-947.
95. Putukian, M., J. B. Kreher, D. B. Coppell, J. L. Glazer, D. B. McKeag, and R. D. White 2011. Attention deficit hyperactivity disorder and the athlete: an American Medical Society for Sports Medicine position statement. Clin. J. Sport Med. 21:392-401.
96. Rabiner, D. L., A. D. Anastopoulos, E. J. Costello, R. H. Hoyle, S. E. McCabe, and H. S. Swartzweder 2009. The misuse and diversion of prescribed ADHD medications by college students. J. Atten. Disord. 13:144-153.
97. Rapoport, J. L., M. S. Buchsbaum, H. Weingartner, T. P. Zahn, C. Ludlow, and E. J. Mikkelsen 1978. Dextroamphetamine: cognitive and behavioral effects in normal and prepubertal boys. Science 199:560-563.
98. Rasmussen, P., and C. Gillberg 2000. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J. Am. Acad. Child Adolesc. Psychiatry 39:1424-1431.
99. Rogers, R. D., A. J. Blackshaw, H. C. Middleton, K. Matthews, K. Hawtin, C. Crowley, et al. 1999. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behavior. Psychopharmacology 146:482-491.
100. Rosa-Neto, P., H. C. Lou, P. Cumming, O. Pryds, H. Karrebaek, J. Lunding, et al. 2005. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity/disorder. Neuroimage 25:868-876.
101. Rosenthal, E. 2012. Not acute myocardial infarction in a teenager due to Adderall XR. Pediatr. Cardiol. 33:679.
102. Sahakian, B. J., and A. M. Owen 1992. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J. Royal Soc. Med. 85:399-402.
103. Schelleman, H., W. B. Bilker, S. E. Kimmel, G. W. Daniel, C. Newcomb, J. P. Guevara, et al. 2012. Methylphenidate and risk of serious cardiovascular events in adults. Am. J. Psychiatry 169:178-185.
104. Schmedje, J. F., C. M. Oman, R. Letz, and E. L. Baker 1988. Effects of scopolamine and dextroamphetamine on human performance. Aviation Space Environ. Med. 59:407-410.
105. Schroeder, S. R., K. Mann-Koepke, C. T. Gualtieri, D. A. Eckerman, and G. R. Breese 1987. Methylphenidate affects strategic choice behavior in normal adult humans. Pharmacol. Biochem. Behav. 28:213-217.
106. Schweitzer, J. B., D. O. Lee, R. B. Hanford, C. F. Zink, T. D. Ely, M. A. Tagamets, et al. 2004. Effect of methylphenidate on executive functioning in adults with attention deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol. Psychiatry 56:597-606.
107. Sciutto, M. J., C. J. Nolfi, and C. Bluhm 2004. Effects of child gender and symptom type on referrals for ADHD by elementary school teachers. J. Emotion Behav. Disord. 12:247-253.
108. Servan-Schreiber, D., C. S. Carter, R. M. Bruno, and J. D. Cohen 1998. Dopamine and the mechanisms of cognition: Part II. D-amphetamine effects in human subjects performing a selective attention task. Biol. Psychiatry 43:723-729.
109. Silber, B. Y., R. J. Croft, K. Papafotiou, and C. Stough 2006. The acute effects of d-amphetamine and methamphtetamine on attention and psychomotor performance. Psychopharmacology 187:154-169.
110. Smith, M. E., and M. J. Farah 2011. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol. Bull. 137:717-741.
111. Soetens, E., R. Dhooge, and J. Hueting 1993. Amphetamine enhances human-memory consolidation. Neurosci. Lett. 161:9-12.
112. Soetens, E., S. Casaer, R. Dhooge, and J. Hueting 1995. Effect of amphetamine on long-term retention of verbal material. Psychopharmacology 119:155-162.
113. Sroufe, L. A. 2012. Ritalin gone wrong. New York Times, 29 January 2012.
114. Strauss, J., J. L. Lewis, R. Klorman, L. J. Peloquin, R. A. Perlmatter, and L. F. Salzman 1984. Effects of methylphenidate on young adults performance and event-related potentials in a vigilance and a paired-associates learning test. Psychophysiology 21:609-621.
115. Surles, L. K., H. J. May, and J. P. Garry 2002. Adderall-induced psychosis in an adolescent. J. Am. Board Fam. Pract. 15:498-500.
116. Sylvester, A. L., and B. Agarwala 2012. Acute myocardial infarction in a teenager due to Adderall XR. Pediatr. Cardiol. 33:155-157.
117. Teter, C. J., S. E. McCabe, J. A. Cranford, C. J. Boyd, and S. K. Guthrie 2005. Prevalence and motivations for the illicit use of prescription stimulants in an undergraduate student sample. J. Am. Coll. Health 53:253-262.
118. The MTA Cooperative Group. 1999. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 56:1073-1086.
119. Tuttle, J. P., N. E. Scheurich, and J. Ranseen 2010. Prevalence of ADHD diagnosis and nonmedical prescription stimulant use in medical students. Acad. Psychiatry 34:220-223.
120. Unrug, A., A. Coenen, and G. van Luijtelaar 1997. Effects of the tranquilizer diazepam and the stimulant methylphenidate on alertness and memory. Neuropsychobiology 36:42-48.
121. Upadhyaya, H. P., K. Rose, W. Wang, K. O'Rourke, B. Sullivan, D. Deas, et al. 2005. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J. Child Adolesc. Psychopharmacol. 15:799-809.
122. Visser, S. N., C. A. Lesesne, and R. Perou 2012. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 119:S99-S107.
123. Vitiello, B., G. R. Elliott, J. M. Swanson, L. E. Arnold, L. Hechtman, H. Abikoff, et al. 2011. Blood pressure and heart rate in the mulimodal treatment of attention deficit/hyperactivity disorder study over 10 years. Am. J. Psychiatry. 169:167-177.
124. Volkow, N. D., Y. S. Ding, J. S. Fowler, G. J. Wang, J. Logan, J. S. Gatley, et al. 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52:456-463.
125. Volkow, N. D., G. J. Wang, J. Newcorn, F. Telang, M. V. Solanto, J. S. Fowler, et al. 2007. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 64:932-940.
126. Volkow, N. D., G. J. Wang, D. Tomasi, S. H. Kollins, T. L. Wigal, J. H. Newcorn, et al. 2012. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J. Neurosci. 32:841-849.
127. Ward, A. S., T. H. Kelly, R. W. Foltin, and M. W. Fischman 1997. Effects of d-amphetamine on task performance and social behavior of humans in a residential laboratory. Exp. Clin. Psychopharmacol. 5:130-136.
128. Weitzner, M. 1965. Manifest anxiety, amphetamine and performance. J. Psychol. 60:71-79.
129. Weyandt, L. L., and G. DuPaul 2006. ADHD in college students. J. Atten. Disord. 10:9-19.
130. Wilens, T. E. 2003. Does the medicating ADHD increase or decrease the risk for later substance abuse? Rev. Bras. Psiquiatr. 25:127-128.
131. Wilens, T. E., J. Biederman, and T. J. Spencer 2002. Attention deficit/hyperactivity disorder across the lifespan. Annu. Rev. Med. 53:113-131.
132. Wilens, T. E., S. Faraone, and J. Biederman 2004. Attention-deficit/hyperactivity disorder in adults. JAMA 292:619-623.
133. Wilens, T. E., L. A. Adler, J. Adams, S. Sgambati, J. Rotrosen, R. Sawtelle, et al. 2008. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry 47:21-31.
134. Willett, R. A. 1962. The effect of a stimulant and a depressant drug on the serial rote learning of nonsense syllables. Psychopharmacologia 3:23-34.
135. Wise, R. A. 2002. Brain reward circuitry: insights from unsensed incentives. Neuron 36:229-240.
136. de Wit, H., J. Crean, and J. B. Richards 2000. Effects of d-amphetamine and ethanol on a measure of behavioral inhibition in humans. Behav. Neurosci. 114:830-837.
137. de Wit, H., J. L. Enggasser, and J. B. Richards 2002. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 27:813-825.
138. Zeeuws, I., and E. Soetens 2007. Verbal memory performance improved via an acute administration of D-amphetamine. Hum. Psychopharmacol. Clin. Exp. 22:279-287.
139. Zuvekas, S., and B. Vitiello 2011. Stimulant medication use in children: a 12-year perspective. Am. J. Psychiatry 169:160-166.